Artificial Blood Market New Business Opportunities and Investment Research Report

Artificial_Blood
Image Credit : digitaltrends

Artificial blood is an artificially developed substitute for red blood cells.For decades, scientists have been trying to develop artificial blood from various sources and through different methods to address the shortage of blood for transfusions. Inadequate number of blood donors and the criticality of blood-type rejection have encouraged researchers to develop artificial blood, thus reducing the dependency on blood donors.

Transfusion of red blood cells (RBCs) is a standard and indispensable therapy for anemic conditions. Blood transfusion process has progressed through various developments, including development of acid-citrate-dextrose blood preservation solution, and cloning of ABO gene. However, blood transfusion come with a high risk of infections. Recombinant erythropoietin stimulating agent therapy has been the prominent therapy in cases such as chronic kidney disease, and chronic anemic conditions. Yet in thrombotic and neoplastic complications, blood transfusion is the only option. Hence, RBC production from hematopoietic stem cells has been the focus of regenerative therapy, with major players investing billions of dollars in R&D related to this technique. However, the final product is yet to receive U.S. Food & Drug Administration (FDA) approval.

Request a sample copy of this [email protected]

https://www.coherentmarketinsights.com/insight/request-sample/11

Artificial Blood Market Development

There has been significant progress made in the global artificial blood market with respect to finding a suitable method to produce blood cells. Scientists have been trying to develop artificial blood from diverse molecules ranging from perfluorocarbons to hemoglobin. With the advent of research in stem cells, researchers began to develop RBCs from stem cells of cord blood. The enrollment for the first clinical trials of stem-cell based red blood cells began in 2009. This study used stem cells from cord blood and adult bone marrow. The study was conducted at the Hematological Laboratory at the University of Paris VI.

A similar research conducted by scientists at the University of Bristol and the UK’s National Health Service (NHS) using stem cells from adult and umbilical cord blood has shown successful results from initial studies. The study is scheduled to enter clinical trials with 20 subjects in 2017. The focus of these trials is to provide special treatment for specific patient groups, rather than act as complete replacement for blood.

Artificial Blood Market Potential

According to the World Health Organization (WHO), there are around 50,000 stem cell transplantations performed annually worldwide, which include 2,000 cord blood hematopoietic stem cell transplants performed each year. Use of stem cells from cord blood is increasing, as it does not require perfect human leukocyte antigen (HLA) tissue matching, can be used allogenically, and has less incidence of graft v/s host disease. According to the New York Blood Center (NYBC), which is the largest cord blood bank globally in terms of units stored, over half of all stem cell transplants in children, in the U.S., use cord blood. A similar statistic has been noted among adults in Japan.

Post the trial in 2017, production is expected to commence in the following 8 to 10 years, thus prolonging the commercialization of product in the artificial blood market.

Artificial Blood Market Future Outlook

Cord blood stem cell transplantation has proved to be a successful therapy in treatment of around 70 diseases. Developing artificial blood can be of great aid to meet the demand-supply gap in blood transfusion, more so considering the fact that finding compatible donors for sickle cell anemia and thalassemia patients is a mammoth task. Development of artificial blood could be the most viable solution to address the unmet needs among these patients. Continued investment in research and development is crucial for ensuring the commercial application of this technology, a very critical factor to contribute towards development of artificial blood market. Being a critical therapy for a severe life condition, the artificial blood market is expected to get a product in a decade or so.

Get Table Of Content:

https://www.coherentmarketinsights.com/ongoing-insight/toc/11

You may be interested

Closed MRI Systems Market – Latest Advancements & Market Outlook 2018 to 2026
Healthcare
Healthcare

Closed MRI Systems Market – Latest Advancements & Market Outlook 2018 to 2026

Pareesh Phulkar - May 21, 2018

Magnetic resonance imaging (MRI) is a non-invasive medical test that uses powerful magnetic field, radio waves, and a computer to produce detailed virtual image of internal organs…

Rising number of surgical procedures coupled with increasing trauma cases to foster global hemostasis & tissue sealing agents market
Healthcare
Healthcare

Rising number of surgical procedures coupled with increasing trauma cases to foster global hemostasis & tissue sealing agents market

Albert R - May 19, 2018

Hemostasis is a physiological processes, which maintains fluidity of blood by preventing blood loss from body. Hemostasis is characterized by clot formation by activating the natural coagulation…

Synovial Sarcoma Treatment Market Regional Insights
Healthcare
Healthcare

Synovial Sarcoma Treatment Market Regional Insights

Albert R - May 19, 2018

Synovial sarcoma consists of abnormal growth of soft-tissue. Synovial sarcoma is a rare type of cancer and is more prevalent in teenagers and young adults. Synovial sarcoma…

Most from this category